BackSofiva Genomics ,Ltd. Overview

Sofiva Genomics ,Ltd. Current Assets

Sofiva Genomics ,Ltd.'s current assets is $240M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$244.91M
↓ 1.03% YoYΔ $-2.55M vs prior year quarter

Peer trimmed avg / median

Loading

Sofiva Genomics ,Ltd. Current Assets History

Loading

Sofiva Genomics ,Ltd. vs. peers: Current Assets Comparison

Loading

Sofiva Genomics ,Ltd. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sofiva Genomics ,Ltd. (6615.TWO) FAQ

Sofiva Genomics ,Ltd. (6615.TWO) currently reports a current assets of $240M as of June 2026. That compares with $250M in the prior-year period — down 1.0% year over year. Use the charts on this page to explore Sofiva Genomics ,Ltd.'s current assets history and peer comparisons.

Sofiva Genomics ,Ltd.'s current assets decreased from $250M to $240M — a 1.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sofiva Genomics ,Ltd. reported $240M in current assets as of June 2026. That compares with $250M in the prior-year period — down 1.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $240M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sofiva Genomics ,Ltd., and consider following 6615.TWO for alerts when major investors trade the stock.